ECSP10010142A - Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas - Google Patents

Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas

Info

Publication number
ECSP10010142A
ECSP10010142A EC2010010142A ECSP10010142A ECSP10010142A EC SP10010142 A ECSP10010142 A EC SP10010142A EC 2010010142 A EC2010010142 A EC 2010010142A EC SP10010142 A ECSP10010142 A EC SP10010142A EC SP10010142 A ECSP10010142 A EC SP10010142A
Authority
EC
Ecuador
Prior art keywords
peptides
amiloids
diagnosis
specific antibodies
new specific
Prior art date
Application number
EC2010010142A
Other languages
English (en)
Inventor
Eugeen Vanmechelen
Pierre Grognet
Nicolas Sergeant
Marie Gompel
Andre Delacourte
Luc Buee
Laurent Pradier
Veronique Blanchard-Bregeon
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010142(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of ECSP10010142A publication Critical patent/ECSP10010142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal que se une específicamente a la región N-terminal de péptidos A?8-x, estando x comprendido desde 11 a 42, y que no reconoce ni A?1-40 ni A?1-42 y que presenta una elevada afinidad con respecto a péptidos A?8-x, tal como se determina mediante la formación de complejo inmunológico entre el anticuerpo monoclonal y el péptido A?8-x.
EC2010010142A 2007-10-29 2010-04-29 Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas ECSP10010142A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119537 2007-10-29

Publications (1)

Publication Number Publication Date
ECSP10010142A true ECSP10010142A (es) 2010-07-30

Family

ID=38925731

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010142A ECSP10010142A (es) 2007-10-29 2010-04-29 Nuevos anticuerpos especificos de los peptidos -amiloides y sus usos como agentes de diagnostico o drogas

Country Status (27)

Country Link
US (1) US8343493B2 (es)
EP (1) EP2205633A1 (es)
JP (1) JP5421277B2 (es)
KR (1) KR20100097651A (es)
CN (1) CN101883792B (es)
AP (1) AP2957A (es)
AR (1) AR069085A1 (es)
AU (1) AU2008317705B2 (es)
CA (1) CA2703825A1 (es)
CL (1) CL2008003197A1 (es)
CO (1) CO6270369A2 (es)
CR (1) CR11396A (es)
EA (1) EA201070539A1 (es)
EC (1) ECSP10010142A (es)
HN (1) HN2010000880A (es)
IL (1) IL205398A0 (es)
MA (1) MA31793B1 (es)
MX (1) MX2010004660A (es)
MY (1) MY155144A (es)
NI (1) NI201000075A (es)
NZ (1) NZ585000A (es)
TN (1) TN2010000197A1 (es)
TW (1) TW200936605A (es)
UA (1) UA103602C2 (es)
UY (1) UY31433A1 (es)
WO (1) WO2009056490A1 (es)
ZA (1) ZA201002989B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
PH12012501744A1 (en) 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
EP2511296A1 (en) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
DK3269736T3 (da) 2012-05-10 2020-01-13 Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin Konformationsspecifikke antistoffer mod oligomerer af amyloid beta
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US10774120B2 (en) * 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Ｃｐｆ１に基づくゲノム編集の治療適用
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
KR102862077B1 (ko) 2018-10-04 2025-09-18 게오르그-아우구스트-우니베시태트 괴팅겐 스티프퉁 외펜틀리헨 레흐츠, 우니베시태츠메디진 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
EP4448564A1 (en) * 2021-12-17 2024-10-23 F. Hoffmann-La Roche AG A novel antibody for detection of amyloid beta 42 (a-beta42)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013172A2 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
ZA201002989B (en) 2011-07-27
WO2009056490A1 (en) 2009-05-07
AR069085A1 (es) 2009-12-30
KR20100097651A (ko) 2010-09-03
MY155144A (en) 2015-09-15
AU2008317705B2 (en) 2014-06-05
MA31793B1 (fr) 2010-10-01
HN2010000880A (es) 2014-03-10
US20110059092A1 (en) 2011-03-10
AP2010005249A0 (en) 2010-06-30
CN101883792B (zh) 2014-08-27
IL205398A0 (en) 2010-12-30
MX2010004660A (es) 2010-07-30
UY31433A1 (es) 2009-05-29
EP2205633A1 (en) 2010-07-14
CN101883792A (zh) 2010-11-10
NZ585000A (en) 2012-08-31
JP5421277B2 (ja) 2014-02-19
UA103602C2 (ru) 2013-11-11
CA2703825A1 (en) 2009-05-07
CR11396A (es) 2012-10-18
JP2011502139A (ja) 2011-01-20
US8343493B2 (en) 2013-01-01
TN2010000197A1 (en) 2011-11-11
CO6270369A2 (es) 2011-04-20
EA201070539A1 (ru) 2010-10-29
CL2008003197A1 (es) 2010-01-15
TW200936605A (en) 2009-09-01
AP2957A (en) 2014-08-31
AU2008317705A1 (en) 2009-05-07
NI201000075A (es) 2010-09-23

Similar Documents

Publication Publication Date Title
UY31433A1 (es) Nuevos anticuerpos especificos de los peptidos - amiloides y sus usos como agentes de diagnostico o drogas
ES2500066T3 (es) Anticuerpos frente a ferroportina y métodos de uso
MX2020001752A (es) Anticuerpos anti-cd3 y metodos de uso.
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
CR11374A (es) Proteinas humanas de union a antigenos del gm-csf
MX384225B (es) ANTICUERPOS IgG BIESPECIFICOS, ACOPLADORES DE LINFOCITOS T.
CR20120127A (es) Anticuerpos monoclonales
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
MX2021013586A (es) Anticuerpo monoclonal anti-antigeno 4 asociado a linfocitos t citotoxicos (ctla4) o su fragmento de union a antigeno, una composicion farmaceutica y uso.
ECSP14013307A (es) Genzyme corporation
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
GT200600186A (es) Agentes de unión
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
GT200900043A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
JO3625B1 (ar) بروتينات رابطة للأنتيجين cd27l
MX2013007371A (es) Peptidos de enlace her2 radiomarcados.
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
MX2013010571A (es) Ensayo de diagnostico de anticuerpo.
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)